review peroxisome proliferator-activated receptor- and its role in the development and treatment of diabetes审查过氧物酶体proliferator-activated受体及其在发展中的作用和治疗糖尿病.pdfVIP

Experimental Diab. Res., 5:99–109, 2004 c Copyright Taylor and Francis Inc. ISSN: 1543-8600 print / 1543-8619 online DOI: 10.1080/15438600490451668 Review: Peroxisome Proliferator-Activated Receptor-γ and Its Role in the Development and Treatment of Diabetes Todd Leff, Suresh T. Mathews, and Heidi S. Camp Department of Pathology and the Center for Integrative Metabolic and Endocrine Research, Wayne State University School of Medicine, Detroit, Michigan, USA; and Department of Metabolic Diseases, Abbott Laboratories, Abbott Park, Illinois, USA of the PPAR subtypes display distinct expression patterns and Since its identification as the receptor for antidiabetic biological functions [1]. The endogenous ligands for all three thiazolidinedione drugs, peroxisome proliferator-activated receptors appear to be derivatives of dietary fatty acids and receptor-γ (PPARγ) has been the focus of pharmaceuti- arachidonate metabolites [2]. PPARα is expressed predomi- cal drug discovery programs directed toward finding bet- nantly in liver, heart, muscle, and kidney, where it positively ter drugs for the treatment of diabetes, as well as the ob- ject of basic research aimed at understanding its role in regulates fatty acid oxidation pathways [3]. This function of the regulation of metabolism. We now understand a great PPARα is consistent with the observation that the fibrate class deal about the crucial role that PPARγ plays in adipocyte of lipid-lowering drugs were found to be activators of PPARα differentiation and development, and are rapidly gaining [4, 5]. The function of PPARδ is much less well understood. knowledge about the role of the receptor in t